Close menu

September 29th, 2022 | 13:17 CEST

Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

  • Technology
  • Biotechnology
  • Investments
Photo credits:

The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

time to read: 3 minutes | Author: Fabian Lorenz

Table of contents:

    Aspermont: A chance of tripling?

    The analysts at GBC Research believe that the Aspermont share has the potential to triple. The Australian B2B service provider for the raw materials industry has strong growth and a high gross margin. As a result, they cite a price target of AUD 0.11. Currently, Aspermont's stock is trading at AUD 0.025. The management of the B2B service provider was recently on a roadshow in Germany. Clearly, with success, as the share price made significant gains, rising to AUD 0.030. The current consolidation is quite healthy and could be used to enter the market. After all, the Company is growing significantly.

    GBC estimates that sales in the current year should climb from AUD 16.10 million to AUD 19.7 million. The gross margin is expected to remain stable at 67.5%. EBITDA is expected to increase from AUD 1.60 million to AUD 2.70 million. Aspermont's business model is based on B2B XaaS sales. The Company is developing an audience-customer ecosystem based on three revenue pillars: Content as a Service (CaaS), Data as a Service (DaaS) and Marketing as a Service (MaaS). The three platforms are built to interact with each other. This scalable model enables high margins and recurring revenue that is scalable across different industries, geographies and languages. As a result, GBC expects Aspermont to continue to achieve significant double-digit revenue and above-average earnings growth in the coming years. Aspermont is debt-free and has more than AUD 7 million in cash, corresponding to a good 20% of the market capitalization.

    BioNTech: Continuing high dividend?

    Since mid-January, the BioNTech share has been in a volatile sideways movement between EUR 120 and EUR 170. The analysts at Berenberg believe this is unjustified. Although the future revenue figure from the sale of the Corona vaccine is uncertain, and the quality of the development pipeline can also be discussed, Berenberg nevertheless sees the share positively. BioNTech, for example, has substantial cash reserves and is willing to share them with shareholders. Therefore, further high dividend payments are to be expected. Thus, the analysts recommend BioNTech stock as a buy with a price target of USD 312. Previously, Deutsche Bank had expressed more cautious views. The sales development in the year to date is below expectations, and no more price-driving news can be expected from the product pipeline this year. Their target price is USD 180.

    Kion: Price targets tumble

    Deutsche Bank also recommends a "hold" on the Kion share. After the latest profit warning, the price target was reduced from EUR 54 to EUR 32. In addition, the analysts have cut their earnings estimates for the forklift manufacturer for the current year by 62%. The experts at Deutsche Bank are also more cautious for the years ahead and reduced the forecasts by 35% on average. They say that regaining confidence will likely cost Kion's management several quarters. DZ Bank also believes it will take several quarters before investors regain the courage to buy Kion shares. They also reacted to the forklift manufacturer's surprisingly severe profit warning by reducing their price target from EUR 55 to EUR 31. However, the analysts are convinced of the longer-term prospects of Kion's business model and continue to recommend buying the stock. In particular, the warehouse automation segment is exciting and will contribute to the growth of the MDAX-listed group, they say. The Kion share is currently trading at just over EUR 20.

    Aspermont is strong in growth, debt-free and appears favorably valued. Also, given the current geopolitical and macroeconomic situation in Europe, the shares of the Australian company can be an interesting addition to the portfolio. BioNTech will likely remain driven by the Corona development in the coming months. A continued high dividend payout could keep shareholders happy until the next blockbuster. Kion has spoiled the mood of shareholders. Until they regain confidence, an operational ray of hope is needed.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author

    Related comments:

    Commented by Juliane Zielonka on March 23rd, 2023 | 08:02 CET

    BioNxt Solutions, Bayer, BioNTech - These pharma stocks offer growth potential

    • Biotechnology
    • research
    • Pharma

    The risk of cancer is increasing worldwide for people over the age of 50. The reasons for this are lack of sleep and exercise, pre-existing diseases and poor nutrition. It has now also been scientifically proven that permanent stress is a cause of Parkinson's disease. According to the WHO, disabilities and deaths due to Parkinson's are increasing faster worldwide than for any other neurological disease. Pharmaceutical and biotech companies are doing everything they can to improve the quality of life of those affected. The Canadian biotech company BioNxt is working on a comparative study to improve a therapy patch for treating Parkinson's and make accompanying drug products scalable. Bayer subsidiary Bluerock Therapeutics is using data from the Apple Watch to research Parkinson's symptoms. And CEO Uğur Şahin of BioNTech has closed a billion-dollar deal in cancer therapy.


    Commented by Stefan Feulner on March 21st, 2023 | 08:37 CET

    Varta, Aspermont, Rheinmetall - Full speed ahead for expansion

    • Innovations
    • Technology
    • Defense

    Changing conditions in terms of broken supply chains, high raw material prices and an uncertain geopolitical situation have put many companies in dire straits since the Corona pandemic, leading to a collapse in sales and liquidity bottlenecks. Nevertheless, few managed to adapt their business models to emerge stronger from the crisis.


    Commented by Stefan Feulner on March 20th, 2023 | 09:37 CET

    Evotec, Defence Therapeutics, Morphosys - Movement in the biotech sector

    • Biotechnology
    • Investments

    Is a new wave of takeovers starting in the biotech sector? Already last year, acquisitions by Big Pharma were expected to increase, but these largely failed to materialize. However, this could accelerate in the current year. On the one hand, pharmaceutical companies, such as vaccine manufacturer Pfizer, have deep pockets and need new innovations for their product portfolio; on the other hand, second-tier stocks are attractive targets due to the strong correction.